closesubmit searchsymbol-pdf

PostDoc

Postdoctoral position in Immunology/Infectious diseases

The Laboratory of Experimental Immunology is a new and energetic group that studies human immunology with a particular interest in the antibody response to HIV and other infectious pathogens. Our goal is to precisely understand the biology of humoral immunity and to use this knowledge to effectively prevent and treat infectious diseases.

To this end, our laboratory works with a wide range of techniques in molecular immunology and facilitates different humanized mouse models. Moreover, we conduct clinical trials that enable us to translate our findings into clinical applications. Our group is dedicated to provide an excellent work environment for pursuing forefront and innovative science, and strongly supports the individual development of all members in our group.

The applicant we are looking for should be highly motivated and excited about science. He/She should be enthusiastic, skilled, and talented to address and solve scientific questions. The applicant should be experienced in the fields of molecular immunology/biology and should be a strong team player. All applicants must hold a Ph.D., M.D. or M.D./Ph.D. degree in cell/molecular biology/immunology or related field and should have demonstrated an outstanding performance through their undergraduate and graduate training. The salary will be based on TV-L.

We are very much looking forward to your application. Please submit your CV, brief statement of your research interest, list of publications and two references to florian.klein@uk-koeln.de or daniela.weiland@uk-koeln.de.

If you have further questions please do not hesitate to contact Prof. Dr. Florian Klein at +49 221 478-89693 or by email florian.klein@uk-koeln.de.

For further information concerning our research the following publications are recommended:

  • Antibodies in HIV-1 Vaccine Development and Therapy. (2013). Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Science.
  • Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. (2015). Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC. Nature.
  • Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization.(2013). Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. Cell.
  • HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. (2012). Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. Nature.